Novo Nordisk reined in its growth forecasts for the year in its second-quarter financial results update, blaming "persistent use of compounded GLP-1s, slower-than-expected market expansion, and competition." Compounding of semaglutide should have come to a halt in the US since the drug was removed from the FDA list of medicines in short supply, but various companies continue to provide compounded GLP-1s under a loophole that allows the sale of 'personalised' formulations
If stored improperlysuch as at room temperature or in freezing conditionsthe medication may lose potency or develop physical changes visible as discoloration or particle formation
The mechanism is well-documented: forced keratinocyte proliferation disrupts the cornified envelope, increasing transepidermal water loss by measurable amounts
doi: 10.3389/fcell.2020.583850 Received 15 July 2020 Accepted 31 August 2020 Published 18 September 2020 Volume 8 - 2020 Edited by Vadivel Ganapathy, Texas Tech University Health Sciences Center, United States Reviewed by David Thwaites, Newcastle University, United Kingdom
It can be even predatory to [offer] promise to someone in their most vulnerable state when we know that its not going to give them what they need, she said
